Related Experiment Videos
A fluorescence polarization assay for cyclic nucleotide phosphodiesterases
Wei Huang1, Yan Zhang, J Richard Sportsman
1Gilead Sciences Inc., Fosler City, CA, USA.
Journal of Biomolecular Screening
|July 5, 2002
Summary
A novel assay technology (IMAP) enables sensitive detection of cyclic nucleotide phosphodiesterases (PDEs) by measuring reaction products. This fluorescence polarization assay is suitable for drug discovery targeting PDEs involved in cellular signaling.
Area of Science:
- Biochemistry
- Enzyme Assays
- Drug Discovery
Background:
- Cyclic nucleotide phosphodiesterases (PDEs) regulate crucial second messengers cyclic AMP (cAMP) and cyclic GMP (cGMP).
- PDEs are increasingly recognized as important drug targets for various therapeutic applications.
- Existing assay methods for PDEs can be complex or lack sensitivity.
Purpose of the Study:
- To develop a homogeneous fluorescence polarization assay for PDE activity.
- To create a sensitive and broadly applicable assay technology for both cAMP- and cGMP-specific PDEs.
- To demonstrate the utility of the assay in standard microplate formats.
Main Methods:
- Development of an assay (IMAP) based on nanoparticle-bound metal cations.
- Detection of PDE reaction products (AMP or GMP) via fluorescence polarization.
- Application of the assay in 384- and 1536-well microplate formats.
Main Results:
- The IMAP assay demonstrated high sensitivity for PDE activity.
- The assay is applicable to both cAMP- and cGMP-hydrolyzing PDEs.
- Successful implementation in high-throughput screening microplate formats was achieved.
Conclusions:
- The developed homogeneous fluorescence polarization assay (IMAP) provides a sensitive tool for PDE research.
- This technology facilitates drug discovery efforts targeting PDEs.
- The assay's adaptability to microplates supports its use in high-throughput screening.